
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple ...
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, …